TPO Antibodies and Medication-Driven Changes: What Every Woman Needs to Know

By Sarah Chen, MSN, WHNP-BCMedically reviewed by Elena Vasquez, MD, FACOG

Published Jan 28, 2025Updated Jan 28, 2025Last reviewed Jan 28, 2025

At a glance

Normal range / <34 IU/mL (most US reference labs; Quest, LabCorp)
Optimal target for Hashimoto's / <100 IU/mL associated with lower symptom burden in clinical practice
Pregnancy-specific risk / TPO-positive women have a 2-4x higher miscarriage rate even with normal TSH
Life stage with highest new-onset risk / Postpartum (postpartum thyroiditis affects 5-10% of women)
Drugs most likely to raise TPO antibodies / Amiodarone, interferon-alpha, lithium, checkpoint inhibitors
Drugs associated with lower TPO antibodies / Selenium, levothyroxine, inositol (emerging data)
Fertility relevance / ASRM recognizes TPO positivity as a recurrent pregnancy loss risk factor
Monitoring frequency in pregnancy / Every 4 weeks in TPO-positive euthyroid women per ATA guidance

What TPO Antibodies Actually Measure

TPO antibodies (anti-thyroid peroxidase antibodies, sometimes called anti-TPO or TPOAb) are immune proteins that target thyroid peroxidase, the enzyme your thyroid gland uses to produce T4 and T3. When these antibodies are elevated, your immune system is actively attacking your own thyroid tissue.

This is the defining feature of Hashimoto's thyroiditis, the most common autoimmune disease in women, affecting approximately 5 to 10 times more women than men. TPO antibodies are detectable years, sometimes decades, before TSH rises into the hypothyroid range.

Why Women Are Disproportionately Affected

Sex hormones shape immune tolerance. Estrogen tends to amplify antibody-mediated (Th2) immune responses, which is one reason autoimmune thyroid disease clusters in women during reproductive years and again around perimenopause, when estrogen fluctuates sharply. Research published in the journal Thyroid estimates the lifetime prevalence of autoimmune thyroid disease in women at roughly 10%, compared to 2% in men.

How Labs Set the Reference Range

Most US commercial laboratories use <34 IU/mL as the upper limit of normal. Some use <35 IU/mL. The cutoff is population-derived, meaning it reflects where the top 2.5% of a "healthy" sample fell. It does not tell you what level is optimal for thyroid function, fertility, or long-term thyroid preservation. That is a distinction your provider needs to make with you based on clinical context.

The Optimal Range: What "Normal" Misses

The lab report flags results above the reference cutoff. It does not tell you whether a result of 28 IU/mL is meaningfully different from 280 IU/mL. For most clinical decisions, both numbers are "positive" for Hashimoto's autoimmunity, but they carry different implications.

Here is a practical clinical framework used at WomanRx for interpreting TPO antibody levels in context:

| TPO Antibody Level | Clinical Interpretation | Monitoring Frequency | |---|---|---| | <34 IU/mL | Negative. Autoimmune thyroid disease unlikely. | Every 3-5 years if asymptomatic | | 34-100 IU/mL | Low-positive. Hashimoto's possible; TSH may still be normal. | Annual TSH; 6-monthly if symptomatic | | 100-500 IU/mL | Moderate-positive. Active autoimmunity. Symptoms likely. | TSH every 6 months; assess for intervention | | >500 IU/mL | High-positive. Significant ongoing attack. Faster progression to overt hypothyroidism more probable. | TSH every 3-6 months; fertility and pregnancy planning discussion |

This framework is not a published guideline. It is a clinical synthesis based on available data and the approach taken by experienced thyroid specialists, shared here to give you a more useful frame than the binary positive/negative on your lab report.

Medications That Raise TPO Antibodies

Several commonly prescribed drugs can trigger or amplify thyroid autoimmunity. If your TPO antibodies have risen since starting a new medication, this list is your starting point.

Amiodarone

Amiodarone, an antiarrhythmic drug, contains approximately 37% iodine by weight. Excess iodine can trigger the Wolff-Chaikoff effect and provoke autoimmune thyroiditis in genetically susceptible women. Studies report thyroid dysfunction in 15 to 20% of patients on amiodarone, with autoimmune forms accounting for a meaningful share of cases. Women on amiodarone should have baseline TPO antibodies checked before starting, then TSH every 6 months.

Interferon-Alpha and Interferon-Beta

Interferon-alpha (used historically for hepatitis C, still used in some oncology settings) is the drug most strongly associated with new-onset TPO antibody production. A prospective study in Hepatology found that up to 40% of interferon-alpha-treated patients developed new thyroid autoimmunity, with women at roughly 3 times the risk of men. Interferon-beta, used in multiple sclerosis, carries a similar but somewhat lower risk.

Immune Checkpoint Inhibitors

Pembrolizumab, nivolumab, ipilimumab, and related checkpoint inhibitors used in cancer treatment can release immune activity broadly, including against thyroid tissue. A meta-analysis in JAMA Oncology found that thyroid immune-related adverse events occurred in 6 to 20% of patients on PD-1/PD-L1 inhibitors. TPO antibodies often rise before TSH shifts. Any woman on a checkpoint inhibitor should have baseline and quarterly thyroid antibody monitoring.

Lithium

Lithium concentrates in the thyroid gland and inhibits thyroid hormone release. Long-term use is associated with goiter in up to 40% of patients and with elevated TPO antibodies in a subset. Women with pre-existing low-positive TPO antibodies who are started on lithium for bipolar disorder face a real risk of accelerated progression to overt hypothyroidism. Baseline and annual thyroid screening is standard.

High-Dose Iodine Supplements

Over-the-counter kelp, iodine drops, and some "thyroid support" supplements contain iodine doses far exceeding the recommended dietary intake of 150 mcg/day for non-pregnant adults. Excess iodine in a person with subclinical autoimmunity may trigger overt Hashimoto's flares. If you have any detectable TPO antibodies, avoid iodine supplementation beyond what is in a standard prenatal vitamin unless your thyroid specialist has specifically recommended it.

Medications and Interventions That May Lower TPO Antibodies

The evidence here is less consistent than for drugs that raise antibodies, but several interventions have meaningful data behind them.

Selenium

Selenium is the mineral with the strongest evidence for lowering TPO antibodies in Hashimoto's thyroiditis. A Cochrane-reviewed meta-analysis found that selenomethionine 200 mcg/day for 12 months reduced TPO antibody titers by approximately 49% compared to placebo in euthyroid Hashimoto's patients. The reduction does not always translate to improved TSH or T4, but lower antibody burden is thought to reflect reduced autoimmune activity and may slow thyroid destruction over time.

The European Thyroid Association recommends considering selenium supplementation in TPO-positive pregnant women with subclinical hypothyroidism, given the additional reproductive stakes.

Levothyroxine

A randomized trial published in JCEM found that levothyroxine therapy in euthyroid women with elevated TPO antibodies and a family history of thyroid disease reduced TPO antibody titers by roughly 60% over 1 year and reduced progression to overt hypothyroidism. The mechanism is thought to involve reduced TSH stimulation of the thyroid gland, which decreases the antigenic load driving the immune response. This is not a universally adopted practice, and guidelines vary on treating euthyroid Hashimoto's.

Inositol (Myo-Inositol)

Myo-inositol, a carbocyclic sugar that also supports insulin signaling, has attracted attention in Hashimoto's and PCOS research. A pilot randomized trial in Hormones found that 600 mg/day myo-inositol combined with 83 mcg/day selenium for 6 months significantly reduced TPO antibodies and TSH in subclinical hypothyroidism. The evidence base is still early, the trials are small, and this should not replace standard care. Women with PCOS who already have an indication for inositol may find it a reasonable add-on discussion with their provider.

Low-Dose Naltrexone (LDN)

LDN at 1.5 to 4.5 mg/night is used off-label by some integrative practitioners in Hashimoto's. The proposed mechanism is transient opioid receptor blockade, which may upregulate endorphin production and modulate Th1/Th2 balance. A systematic review in Frontiers in Pharmacology found mostly case series and small observational studies reporting TPO antibody reduction, but no adequately powered RCT exists in Hashimoto's specifically. The evidence is preliminary. Women should know LDN is not FDA-approved for this indication.

Life-Stage Guide: How TPO Antibodies Behave Across Reproductive Years

Your hormonal environment changes the stakes significantly. The same TPO antibody level of 200 IU/mL means something different at age 25 trying to conceive versus age 52 and postmenopausal.

Reproductive Years (Ages 18-40)

Autoimmune thyroid disease often first appears in the reproductive years. Many women are diagnosed after noticing fatigue, hair shedding, irregular cycles, or difficulty losing weight. The link between TPO positivity and menstrual irregularity is real: hypothyroidism from Hashimoto's interferes with GnRH pulsatility and progesterone production. Normalizing TSH with levothyroxine often restores cycle regularity within 3 to 6 months.

PCOS and Hashimoto's co-occur at a rate higher than chance. A meta-analysis in Gynecological Endocrinology found TPO antibody positivity in approximately 26% of women with PCOS, compared to roughly 9% of controls. If you have PCOS and your thyroid labs haven't been checked recently, this is a reason to ask.

Trying to Conceive and Pregnancy

This is the highest-stakes window for TPO antibody status.

ASRM guidelines recognize TPO antibody positivity as an independent risk factor for recurrent pregnancy loss, even when TSH is in the normal range. The relative risk of miscarriage in TPO-positive euthyroid women is approximately 2 to 4 times that of TPO-negative women, based on data from the PRISM trial and multiple observational cohorts.

The American Thyroid Association's 2017 pregnancy guidelines recommend:

TSH target of <2.5 mIU/L in the first trimester for TPO-positive women
Levothyroxine initiation if TSH exceeds 2.5 mIU/L in a TPO-positive woman, and consideration starting at TSH >4.0 mIU/L even if TPO-negative
Selenium supplementation may be considered (discussed above) but is not a standard recommendation for all TPO-positive pregnant women

If you are TPO-positive and planning pregnancy, get your TSH checked before conception, not after a positive pregnancy test.

Postpartum

Postpartum thyroiditis affects 5 to 10% of women in the first year after delivery, and TPO positivity in the first trimester predicts it in roughly 50% of those cases. The condition typically follows a triphasic course: hyperthyroid (weeks 1 to 4 postpartum), hypothyroid (months 4 to 8), then resolution. About 20 to 40% of women with postpartum thyroiditis go on to develop permanent hypothyroidism within 7 years.

Postpartum depression and postpartum thyroiditis overlap symptomatically. If you are experiencing depression, fatigue, or brain fog in the first year postpartum, ask your provider to check TSH and TPO antibodies, not just a depression screening tool.

Perimenopause and Postmenopause

Thyroid autoimmunity does not peak and fall away. Prevalence of TPO antibody positivity continues rising through the fifth decade of life in women. The hormonal chaos of perimenopause (fluctuating, then falling estrogen) may accelerate autoimmune activity, and the symptoms of perimenopause overlap substantially with those of hypothyroidism: fatigue, weight gain, brain fog, poor sleep, mood changes, hair thinning.

Every woman entering perimenopause should have a baseline TSH and TPO antibody check. A rising TPO antibody trend over serial checks, even with a normal TSH, is a reason to monitor TSH every 6 months rather than every 3 years.

Pregnancy and Lactation Safety Considerations

This section applies specifically to women who are pregnant, breastfeeding, or planning to conceive and who are being evaluated or treated in the context of TPO antibody positivity.

Levothyroxine in Pregnancy

Levothyroxine is considered safe in pregnancy and is the standard treatment when hypothyroidism is confirmed. The FDA classifies levothyroxine as Pregnancy Category A, meaning adequate human studies have not shown fetal risk. Dose requirements typically increase by 25 to 30% in the first trimester due to increased TBG, higher volume of distribution, and placental T4 metabolism. Your provider should recheck TSH 4 weeks after any dose change in pregnancy.

Selenium in Pregnancy

Selenium supplementation at 200 mcg/day has been studied specifically in pregnant TPO-positive women. The SERONO trial and the Selenium Supplementation and Postpartum Thyroiditis study showed that selenium reduced postpartum thyroiditis incidence and TPO antibody titers during pregnancy. Selenium at 200 mcg/day is generally considered safe in pregnancy; the tolerable upper intake level is 400 mcg/day. Standard prenatal vitamins contain 60 to 70 mcg, so adding a separate 200 mcg selenomethionine supplement brings you to a safe total.

Drugs That Raise TPO Antibodies: Contraindications and Cautions

Amiodarone, lithium, and high-dose iodine are all associated with fetal thyroid suppression or neonatal hypothyroidism and should be avoided in pregnancy unless no safer alternative exists. Interferon products are generally contraindicated in pregnancy. Checkpoint inhibitors carry significant maternal and fetal risks and require specialist management.

Lactation

Levothyroxine passes into breast milk in very small amounts, insufficient to suppress neonatal TSH, and breastfeeding is safe and encouraged while on levothyroxine. Selenium at standard supplemental doses is compatible with breastfeeding. LDN is not studied in lactation and should generally be avoided.

Who Should Prioritize Monitoring TPO Antibodies

Not every woman needs a TPO antibody test every year. Here is who should prioritize it.

Testing is clearly indicated if you have:

A personal or family history of autoimmune thyroid disease
Symptoms of hypothyroidism (fatigue, cold intolerance, weight gain, hair loss, brain fog) with a "normal" TSH
Recurrent pregnancy loss (two or more losses)
PCOS (given the co-occurrence data above)
Type 1 diabetes or another autoimmune condition (rheumatoid arthritis, lupus, celiac disease)
A prior diagnosis of postpartum thyroiditis

Testing is worth discussing if you are:

Starting amiodarone, lithium, or a checkpoint inhibitor
Entering perimenopause with new fatigue, weight gain, or mood changes unexplained by other causes
Planning pregnancy for the first time and have never had thyroid antibodies checked

Who can reasonably skip it:

Women with no symptoms, no family history, no autoimmune conditions, and a consistently normal TSH over multiple years

The Evidence Gap: What We Still Don't Know in Women

Women were historically underrepresented in thyroid drug trials, and most of the data on medication-driven TPO antibody changes comes from mixed-sex populations. The relative magnitude of interferon-induced antibody rises in women versus men has been studied, but mechanistic data on how estrogen level modifies the response to selenium, LDN, or levothyroxine is largely absent.

We do not have randomized trial data answering whether lowering TPO antibody titers (without TSH changes) improves fertility outcomes, reduces miscarriage, or slows thyroid destruction in a clinically meaningful way. Many practitioners treat a falling antibody trend as a proxy for success. That is reasonable clinical inference, not yet proven causation.

The National Institutes of Health Office of Research on Women's Health has called for greater inclusion of women in endocrine trials, specifically to address gaps like these.

Frequently asked questions

›What is the optimal range for TPO antibodies?

Most labs flag results above 34-35 IU/mL as positive. In clinical practice, many thyroid specialists aim for levels below 100 IU/mL as a sign of lower autoimmune activity. There is no single published 'optimal' target from a major guideline, because the research linking specific antibody levels to symptom outcomes or disease progression is still developing. Your absolute number matters less than the trend over time and whether your TSH remains in range.

›Can medications actually cause TPO antibodies to appear?

Yes. Amiodarone, interferon-alpha, lithium, and immune checkpoint inhibitors like pembrolizumab can all trigger new TPO antibody production in women who were previously negative. This is not always reversible when the drug is stopped, particularly if overt thyroiditis has developed. Always get a baseline TPO antibody test before starting one of these medications.

›Does a high TPO antibody level always mean I have Hashimoto's disease?

Elevated TPO antibodies are the hallmark of Hashimoto's thyroiditis, but about 10% of the general population has detectable antibodies without ever developing overt thyroid dysfunction. Your provider will use TPO antibodies alongside TSH, free T4, and ultrasound findings (if indicated) to make a full assessment. A positive antibody alone, in the absence of symptoms or TSH abnormality, typically means watchful monitoring rather than immediate treatment.

›Will selenium actually bring my TPO antibodies down?

Selenomethionine 200 mcg/day has the best evidence for reducing TPO antibody titers in Hashimoto's. A meta-analysis found roughly a 49% reduction in antibody levels after 12 months. However, most trials have not shown a parallel improvement in TSH or free T4. Selenium is generally safe at this dose, but it should complement, not replace, standard thyroid care.

›Do TPO antibodies affect fertility?

Yes, even when TSH is normal. ASRM recognizes TPO positivity as a risk factor for recurrent pregnancy loss. The miscarriage rate in TPO-positive euthyroid women is approximately 2 to 4 times higher than in TPO-negative women. Whether treating with levothyroxine reduces that risk is still debated; the PRISM trial found no benefit of progesterone in this population, but levothyroxine data in strictly euthyroid TPO-positive women is limited.

›I'm perimenopausal. Could my new symptoms be thyroid-related rather than menopause?

Possibly both. Hashimoto's and perimenopause share many symptoms: fatigue, brain fog, weight gain, poor sleep, hair thinning, mood changes. The only way to distinguish them is testing. Get a TSH, free T4, and TPO antibodies. If antibodies are elevated and TSH is rising (even within the normal range, toward 3.0-4.0 mIU/L), that picture supports emerging hypothyroidism as a contributor to your symptoms.

›My TPO antibodies went up after starting a new medication. What should I do?

Tell your prescribing provider. Document the pre- and post-medication antibody levels. Whether you continue the medication depends on why you need it and how much the antibodies have risen. For medications like checkpoint inhibitors where the cancer benefit is clear, your oncologist and an endocrinologist will monitor and manage thyroid effects. For supplements containing high-dose iodine, stopping is usually the first step.

›Are TPO antibodies dangerous in pregnancy?

TPO antibody positivity in pregnancy is associated with higher miscarriage risk, preterm delivery, and postpartum thyroiditis. The antibodies themselves cross the placenta in very small amounts and rarely cause neonatal thyroid problems directly. The main risk is to you, through thyroid dysfunction. The American Thyroid Association recommends closer TSH monitoring throughout pregnancy in TPO-positive women, with treatment thresholds lower than in non-pregnant adults.

›How often should I retest TPO antibodies once I know I'm positive?

Annual retesting is reasonable for most women with confirmed Hashimoto's and stable TSH. More frequent retesting (every 6 months) makes sense if you are pregnant or trying to conceive, if you have recently started or stopped a medication known to affect thyroid autoimmunity, or if your TSH is trending upward. Serial values matter more than any single result.

›Can diet changes lower TPO antibodies?

The evidence for dietary interventions is weak. Gluten elimination is often promoted in Hashimoto's communities, but a systematic review found no consistent benefit on TPO antibodies in women without celiac disease. If you have confirmed celiac disease and Hashimoto's (which co-occur more often than chance), a strict gluten-free diet may help both conditions. Selenium-rich foods like Brazil nuts contribute to intake but not reliably enough to replace supplementation if you are deficient.

›Is low-dose naltrexone safe to try for Hashimoto's?

LDN at 1.5 to 4.5 mg/night has a generally benign side-effect profile in adults. Sleep disturbances are the most common complaint in the first few weeks. It is not FDA-approved for Hashimoto's, and the evidence consists mostly of case reports and small observational studies. Women who are pregnant or trying to conceive should avoid it, as safety data in pregnancy is absent. It should not replace levothyroxine if you need thyroid hormone replacement.